2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-139681
    Dopamine D3 receptor antagonist-2 3052236-39-9 98%
    Dopamine D3 receptor antagonist-2 is a dopamine D3 receptor-selective (Ki = 2.16 nM) or multitarget bitopic ligand potentially useful for central nervous system disorders.
    Dopamine D3 receptor antagonist-2
  • HY-139708
    NMDA receptor antagonist-3 2762181-52-0 98%
    NMDA receptor antagonist-3, a NMDA receptor antagonist, stands out with a remarkable percentage of recovery (40.0%, at 100 μM) and safe toxicological profile in SH-SY5Y and human adipose mesenchymal stem cells.
    NMDA receptor antagonist-3
  • HY-139720
    β-Secretase Inhibitor III 2760674-85-7 98%
    β-Secretase Inhibitor III is an extremely selective BACE1 inhibitor (Ki = 0.13 nM).
    β-Secretase Inhibitor III
  • HY-139723
    Antidepressant agent 2 2822600-09-7 98%
    Antidepressant agent 2 exerts pronounced antidepressant activity (MED 0.1 mg/kg).
    Antidepressant agent 2
  • HY-139730
    c-ABL-IN-1 2304918-82-7 98%
    c-ABL-IN-1 is a novel selective c-Abl inhibitor that prevents neurodegeneration in parkinson’s disease.
    c-ABL-IN-1
  • HY-139740
    Aβ Fibrillization modulator 1 2847131-53-5 98%
    Aβ Fibrillization modulator 1 stabilizes Aβ monomers.
    Aβ Fibrillization modulator 1
  • HY-13976A
    PRL-8-53 51352-87-5 98%
    PRL-8-53 is an orally active, blood-brain barrier-permeable benzoate derivative with potent spasmolytic activity and central nervous system regulatory activity. PRL-8-53 acts on dopamine, serotonin and cholinergic-related targets, enhances dopamine activity, partially inhibits serotonin function and elicits cholinergic responses, thereby maintaining neurotransmitter balance in the central nervous system. PRL-8-53 improves learning ability, short-term memory and long-term memory in animals. PRL-8-53 can be used in central nervous system-related research.
    PRL-8-53
  • HY-139802
    L-779976 214770-19-1 98%
    L-779976 is a compound with bradykinin agonist activity. Injection into the amygdala and septum of the rat brain can produce anxiolytic effects. Its bradykinin agonist activity has been verified by relevant experiments.
    L-779976
  • HY-139816
    BTNPO 2507992-93-8 98%
    BTNPO is a unimolecular two-photon fluorescent probe.
    BTNPO
  • HY-139820
    FTO-IN-4 2763577-74-6 98%
    FTO-IN-4 is a potent and selective inhibitor of fat mass obesity-associated protein (FTO).
    FTO-IN-4
  • HY-139821
    FTO-IN-5 2763577-75-7 98%
    FTO-IN-5 is a potent and selective inhibitor of fat mass obesity-associated protein (FTO).
    FTO-IN-5
  • HY-139830
    Dyrk1A-IN-1 2858696-72-5 98%
    Dyrk1A-IN-1 is a triple inhibitor of Dyrk1A kinase activity (IC50 = 119 nM) and the aggregation of tau and α-syn oligomers.
    Dyrk1A-IN-1
  • HY-139871
    hTrkA-IN-2 2986533-14-4 98%
    hTrkA-IN-2 is a selective hTrkA allosteric inhibitor with an IC50 value of 3.9 nM.
    hTrkA-IN-2
  • HY-13993B
    Ro 25-6981 hydrochloride 919289-58-0 98%
    Ro 25-6981 hydrochloride is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 hydrochloride shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 hydrochloride has the potential for the research of parkinson's disease (PD).
    Ro 25-6981 hydrochloride
  • HY-139974
    BChE-IN-2 98%
    BChE-IN-2 (compound 22) is a potent inhibitor of BChE with a Ki of 0.099 μM. BChE-IN-2 is a pyrimidine and pyridine derivative. BChE-IN-2 has the potential for the research of Alzheimer’s disease (AD) .
    BChE-IN-2
  • HY-141468
    β-Chlornaltrexamine dihydrochloride 67025-98-3 98%
    β-Chlornaltrexamine dihydrochloride (β-CNA dihydrochloride) is a potent long-term opioid receptor blocker. β-Chlornaltrexamine dihydrochloride can effectively block the inhibitory effect of κ opioid receptor agonists on dopamine release. β-Chlornaltrexamine dihydrochloride can be used to study the mechanism of pain perception.
    β-Chlornaltrexamine dihydrochloride
  • HY-141489
    DSPE-PEG2000-Carboxy NHS sodium 98%
    DSPE-PEG2000-Carboxy NHS sodium is a linker. DSPE-PEG2000-Carboxy NHS sodium enables conjugation of targeting peptides to lipid nanoparticles after their preparation. DSPE-PEG2000-Carboxy NHS sodium is applicable to the research of hereditary retinal degeneration.
    DSPE-PEG2000-Carboxy NHS sodium
  • HY-141496
    A-77636 778546-51-3 98%
    A-77636 is an orally active, potent, selective and long-acting dopamine D1 receptor agonist (pEC50 = 8.13; EC50 = 1.1 nM). A-77636 shows the highest affinity (pKi = 7.40 ± 0.09; Ki = 39.8 nM) for the dopamine D1 receptor. A-77636 shows antiparkinsonian activity.
    A-77636
  • HY-141541
    MPT0G413 2241643-23-0 98%
    MPT0G413 (Compound 6) is a potent, selective, orally active and brain-penetrant HDAC6 inhibitor with an IC50 of 3.92 nM. MPT0G413 decreases not only the level of phosphorylation of tau proteins but also the aggregation of tau proteins. MPT0G413 can ameliorate the impaired learning and memory. MPT0G413 can be used for the research of neurological disease, such as Alzheimer's disease.
    MPT0G413
  • HY-141564
    RyR1-IN-1 2837939-81-6 98%
    RyR1-IN-1 (Compound 1) is a RyR1 inhibitor with an IC50 of 12 nM. RyR1-IN-1 blocks Ca²⁺ release and inhibits muscle tetany caused by caffeine and heat stress. RyR1-IN-1 can completely prevent the increase in body temperature and death caused by isoflurane and heat stress. RyR1-IN-1 can be used for the study of heat stroke.
    RyR1-IN-1
Cat. No. Product Name / Synonyms Application Reactivity